Chemcrux Q1 FY27: PAT turns around YoY to ₹0.51 Cr, down 73% QoQ as Kalichem drags

Chemcrux Enterprises' consolidated PAT for Q1 FY27 came in at ₹0.51 Cr on revenue of ₹21.94 Cr, against a near-nil ₹0.09 Cr profit a year ago — a YoY turnaround, but off such a thin base that the percentage gain (+445%) overstates the underlying improvement. Sequentially, the print is weaker: revenue fell 9.6% and PAT fell 72.7% from Q4 FY26's ₹24.28 Cr revenue and ₹1.85 Cr PAT, and net margin compressed to 2.29% of total income from 7.51% last quarter (still above the 0.55% margin a year ago). The margin squeeze sits mostly below the operating line: consolidated PBT of ₹0.98 Cr trails standalone PBT of ₹1.85 Cr by ₹0.87 Cr, driven by higher finance costs and depreciation from subsidiary Kalichem Private Limited, plus lower other income at the group level. Standalone core profitability actually held up well — ₹1.37 Cr PAT and EPS of ₹0.93 versus consolidated EPS of ₹0.34 — meaning the group-level miss is a Kalichem-specific drag rather than a deterioration in the core bulk drug intermediates business. This lines up with Kalichem's May 2026 filing of a CTE amendment for inorganic chemicals, consistent with ramp-up costs ahead of expanded capacity. The quarter's employee expense also carries a proportionate charge for the 1,07,700 ESOPs granted on 15 May 2026 (1-year vesting, ₹10 exercise price), per the filing's notes. There is no formal analyst coverage of Chemcrux — a web check found zero analysts submitting estimates for the stock — so the print cannot be benchmarked against street consensus; vsStreet is unknown. The company also carries no prior formal guidance or outlook on record in our data, and no management press release accompanied this filing, so there is no stated targets to grade the quarter against. Other developments this quarter include the board's approval of a 10% final FY26 dividend and the incorporation of a wholly-owned non-profit subsidiary, Chemcrux Foundation (17 July 2026) — neither has a direct bearing on the P&L. Going into Q2 FY27, the read is: standalone operations are stable to improving YoY, but consolidated results will stay under pressure until Kalichem's ramp-up costs are absorbed by higher utilisation or revenue contribution.